Form 4: Adverum Officer's Holdings Post-Eli Lilly Merger

Adverum Biotechnologies' Chief Development Officer reports changes in beneficial ownership following the company's acquisition by Eli Lilly and Company, converting shares, RSUs, PSUs, and options into cash and contingent value rights.

Summary

• Seyedkazemi Setareh, Chief Development Officer of Adverum Biotechnologies, Inc., reported changes in beneficial ownership following the company's acquisition by Eli Lilly and Company.
• The merger, effective December 9, 2025, resulted in Adverum Biotechnologies, Inc. becoming a wholly-owned subsidiary of Eli Lilly and Company.
• Common stock shareholders received $3.56 per share in cash plus one non-tradable contingent value right (CVR), which represents the contractual right to receive up to an aggregate of $8.91 per CVR upon achievement of specified milestones.
• The reporting person's 54,874 shares of common stock were disposed of in exchange for the cash consideration and CVRs.
• 8,125 Restricted Stock Units (RSUs) were cancelled, with the holder receiving cash equal to the product of the number of shares subject to the RSU multiplied by the cash consideration, plus one CVR per RSU share.
• 85,000 Performance Stock Units (PSUs) vested on September 12, 2025, due to the change of control (merger closing), and subsequently 88,332 PSUs were cancelled under similar terms as RSUs.
• Stock options with an exercise price equal to or greater than the $3.56 cash consideration were fully vested prior to the effective time and then cancelled for no consideration. This included options with exercise prices of $10.14, $7.5, $7.15, and $4.2, totaling 208,208 options.

Sentiment

Score: 6

Explanation: The filing reports the expected outcome of a completed merger, converting equity holdings into cash and CVRs. While the merger itself provides a defined exit for shareholders, the cancellation of out-of-the-money options for no consideration represents a loss of potential value for the option holder, leading to a neutral to slightly positive sentiment for the reporting person.

Positives

• The completion of the merger provides a defined cash payout and potential future value through CVRs for shareholders and equity holders.
• 85,000 Performance Stock Units vested due to the change of control, converting potential future value into immediate consideration.
• Out-of-the-money stock options were fully vested prior to cancellation, ensuring all conditions were met before their termination.

Negatives

• Stock options with exercise prices above the cash consideration were cancelled for no consideration, meaning the holder did not realize value from these options.
• The Contingent Value Rights (CVRs) are non-tradable, limiting liquidity for the contingent payments.

Risks

• The primary risk for CVR holders is the non-achievement of specified milestones, which would result in no contingent cash payments.

Future Outlook

Adverum Biotechnologies, Inc. is now a wholly-owned subsidiary of Eli Lilly and Company. Future contingent cash payments are possible for CVR holders upon the achievement of specified milestones as outlined in the CVR Agreement.

Industry Context

This transaction reflects a common trend in the biopharmaceutical industry where larger pharmaceutical companies acquire smaller biotech firms, often to gain access to promising drug candidates, technology platforms, or specialized expertise. Such acquisitions frequently involve a combination of upfront cash and contingent value rights to mitigate risk and incentivize future performance based on clinical or regulatory milestones.

Comparison to Industry Standards

• The use of a cash component combined with Contingent Value Rights (CVRs) is a standard mechanism in biopharma M&A, particularly when the acquired company's assets have significant future value tied to clinical or regulatory success. This structure allows the acquirer (Eli Lilly) to defer a portion of the payment until specific milestones are met, aligning the interests of the former shareholders with the future success of the acquired assets.
• Similar CVR structures have been observed in other biopharma acquisitions, such as Sanofi's acquisition of Kadmon Holdings or Bristol Myers Squibb's acquisition of MyoKardia, where CVRs were tied to regulatory approvals or sales milestones.
• The cancellation of out-of-the-money options for no consideration is also standard practice in such mergers, as these options hold no intrinsic value above the acquisition price.

Corporate Governance

Related Party Transactions

• The merger itself is a significant transaction between Adverum Biotechnologies, Inc. and Eli Lilly and Company, which became a related party upon the acquisition.

Stakeholder Impact

• Shareholders of Adverum Biotechnologies, Inc. received cash and Contingent Value Rights (CVRs) for their common stock, providing a liquidity event and potential future value.
• Employees holding equity awards, such as the reporting person, had their Restricted Stock Units (RSUs), Performance Stock Units (PSUs), and stock options converted or cancelled according to the merger terms.
• Adverum Biotechnologies, Inc. employees are now part of a wholly-owned subsidiary of Eli Lilly and Company, potentially impacting their employment terms and benefits.

Next Steps

• Achievement of specified milestones for potential contingent cash payments to CVR holders.

Key Dates

Keywords

Adverum Biotechnologies, Eli Lilly, Merger, Acquisition, Form 4, Beneficial Ownership, Contingent Value Rights, CVR, Stock Options, Restricted Stock Units, Performance Stock Units, Biotechnology, Pharmaceuticals